Recursion Pharmaceuticals/RXRX

$15.51

5.08%
-
1D1W1MYTD1YMAX

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio biotechnology company. It is focused on utilizing advanced technologies in biology, chemistry, automation, and computer science to discover and design therapeutics. The Company’s platform, Recursion Operating System (OS), is built with diverse technologies and enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. It integrates physical and digital components as iterative loops of atoms and bits of wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of cerebral cavernous malformation (CCM). REC-2282 is developed for the treatment of neurofibromatosis type 2.

Ticker

RXRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Christopher Gibson

Employees

500

Headquarters

Salt lake city, United States

RXRX Metrics

BasicAdvanced
$2.89B
Market cap
-
P/E ratio
-$1.48
EPS
-
Beta
-
Dividend rate

What the Analysts think about RXRX

Analyst Ratings

Majority rating from 7 analysts.
Hold

Price Targets

Average projection from 6 analysts.
20.5% downside
High $15.00
Low $9.00
$15.51
Current price
$12.33
Average price target

RXRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-885.71% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$10.5M
-4.55%
Net income
$-93M
21.25%
Profit margin
-885.71%
27.03%

RXRX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 11.69%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.31
-$0.34
-$0.38
-$0.43
-
Expected
-$0.29
-$0.35
-$0.37
-$0.39
-$0.45
Surprise
6.9%
-2.3%
1.53%
11.69%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Recursion Pharmaceuticals stock

Buy or sell Recursion Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing